Assessment of the impairment of the serotoninergic system during the prodromal phase of Parkinson’s disease in SNCA mutation carriers by PET using [11C]DASB and [11C]SB207145 : SerIAL-PD

Conditions

Parkinson's disease, Prodromal phase of Parkinson's disease

Brief summary

Determine PET-binding potential of radiotracer ligands [11C]DASB and [11C]SB207145 to respective serotonin transporter SERT and receptor 5-HT4, and compare between SNCA+ PD- participants and SNCA- PD- participants.

Detailed description

Determine PET-binding potential of radiotracer ligands [11C]DASB and [11C] SB207145, and compare results between all groups., Determine correlations between PET-binding potential of radiotracer ligands [11C]DASB and [11C] SB207145 and scores on motor and non-motor symptom assessment scales, and compare results between all groups., Determine correlations between PET-binding potential of radiotracer ligands [11C]DASB and [11C] SB207145, DaTSCAN results, and neuromelanin-sensitive MRI (NM-MRI)) results, and compare results between all groups., Determine correlations between PET-binding potential of radiotracer ligands [11C]DASB and [11C] SB207145, DaTSCAN results, neuromelanin-sensitive MRI (NM-MRI) results, scores on motor and non-motor symptom assessment scales, and measurements of blood and cerebrospinal biomarkers, and compare results between all groups., Determine the difference between anatomical and functional MRI images between groups and correlations with clinical scores and PET data.

Related papers

No related papers found yet.

Interventions

DRUG11C-SB207145

DRUG11C-DASB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Determine PET-binding potential of radiotracer ligands [11C]DASB and [11C]SB207145 to respective serotonin transporter SERT and receptor 5-HT4, and compare between SNCA+ PD- participants and SNCA- PD- participants.	—

Secondary

Measure	Time frame
Determine PET-binding potential of radiotracer ligands [11C]DASB and [11C] SB207145, and compare results between all groups., Determine correlations between PET-binding potential of radiotracer ligands [11C]DASB and [11C] SB207145 and scores on motor and non-motor symptom assessment scales, and compare results between all groups., Determine correlations between PET-binding potential of radiotracer ligands [11C]DASB and [11C] SB207145, DaTSCAN results, and neuromelanin-sensitive MRI (NM-MRI)) results, and compare results between all groups., Determine correlations between PET-binding potential of radiotracer ligands [11C]DASB and [11C] SB207145, DaTSCAN results, neuromelanin-sensitive MRI (NM-MRI) results, scores on motor and non-motor symptom assessment scales, and measurements of blood and cerebrospinal biomarkers, and compare results between all groups., Determine the difference between anatomical and functional MRI images between groups and correlations with clinical scores and PET	—

Measure

Time frame

Determine PET-binding potential of radiotracer ligands [11C]DASB and [11C] SB207145, and compare results between all groups., Determine correlations between PET-binding potential of radiotracer ligands [11C]DASB and [11C] SB207145 and scores on motor and non-motor symptom assessment scales, and compare results between all groups., Determine correlations between PET-binding potential of radiotracer ligands [11C]DASB and [11C] SB207145, DaTSCAN results, and neuromelanin-sensitive MRI (NM-MRI)) results, and compare results between all groups., Determine correlations between PET-binding potential of radiotracer ligands [11C]DASB and [11C] SB207145, DaTSCAN results, neuromelanin-sensitive MRI (NM-MRI) results, scores on motor and non-motor symptom assessment scales, and measurements of blood and cerebrospinal biomarkers, and compare results between all groups., Determine the difference between anatomical and functional MRI images between groups and correlations with clinical scores and PET

—

Countries

France

Outcome results

None listed